• Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

  • Feb 10 2025
  • Duración: 20 m
  • Podcast

Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:

    • Early results with teclistamab combined with anti-CD38 therapy
    • Real-world data with teclistamab including its use after other BCMA-targeted therapies
    • Talquetamab as bridging therapy to BCMA-targeted CAR T-cell therapy
    • Evaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapy

    Presenter:
    Shaji K. Kumar, MD
    Mark and Judy Mullins Professor of Hematologic Malignancies
    Consultant, Division of Hematology
    Professor of Medicine
    Chair, Myeloma, Amyloidosis and Dysproteinemia Group
    Research Chair, Division of Hematology
    Associate Chair for Research, Department of Medicine
    Mayo Clinic
    Rochester, Minnesota

    Link to full program:
    https://bit.ly/40bjFCZ
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles